The demand for #COVID19 antibody testing continues to increase, as does the scrutiny regarding tests’ accuracy. While #CDC guidelines have shown that less than half of those testing positive for COVID-19 antibodies actually have them, increasing the number of tests conducted, particularly in areas of high disease prevalence, boosts positive predictive value. This NPR article shows how prevalence and false positive rates affect antibody test results and why using two different tests, which the CDC now recommends for those who test positive, could improve testing accuracy.
As a result of these CDC guidelines, our client BioDot, which provides dispensing automation and manufacturing solutions to the world’s largest diagnostic companies, continues to scale up its manufacturing operations to keep pace with testing demand. The company recently announced that more than 50 companies worldwide are now using its technology to develop #COVID19 #antibody tests. Each of its automated lateral flow dispensing platforms enable customer production of 1 million point-of-care antibody tests per week. Read more in this SelectScience piece.
In COVID-19-related #telemedicine news, our client Prospero Health, a team-based home health care company, has partnered with GrandPad to improve access to care for seniors during the crisis and address gaps in care coordination. Prospero can now provide 24/7 telemedicine support to its vulnerable patients through GrandPad’s video chat capabilities that enable care teams to regularly check in on patients in real-time, while adhering to social distancing guidelines. This story on South Carolina Public Radio highlights how Prospero and GrandPad are contributing to the promise of virtual medical care, which went from being the future to being the new norm.